Clinical trial
Lymphocyte Therapy in Treating Patients With Kidney Cancer
NCT00002589 · National Cancer Institute (NCI), NIH · Unknown status
Key facts
| NCT number | NCT00002589 |
|---|---|
| Title | Lymphocyte Therapy in Treating Patients With Kidney Cancer |
| Official title | Adjuvant Autolymphocyte Therapy (ALT) For Patients With Non-Metastatic Renal Cell Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Biological, Procedure |
| Interventions | aldesleukin, muromonab-CD3, therapeutic autologous lymphocytes, adjuvant therapy |
| Enrollment | 90 |
| Start date | Jul 1, 1994 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: